Bradley and David Wells leave Sauflon following transition period after $1.2bn acquisition

David and Bradley Wells have left their positions as joint managing directors of Sauflon Pharmaceutical held during the transition period since the acquisition of Sauflon by CooperVision for $1.2bn last August.

The Wells brothers have now handed over the responsibilities within the company and officially left the business on February 6. The deal cleared its final regulatory hurdle late last year following the publication of a ruling by the Competition Markets Authority.

Dan McBride President of CooperVision commented: ‘We are grateful to David and Bradley for all of their hard work, and for their part in helping to create a strong market-leading business. We wish them all the best in their future endeavours.’